{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:51:50Z","timestamp":1761486710947},"reference-count":18,"publisher":"Wiley","issue":"11-12","license":[{"start":{"date-parts":[[2002,1,21]],"date-time":"2002-01-21T00:00:00Z","timestamp":1011571200000},"content-version":"vor","delay-in-days":51,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2001,12]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Invasive fungal infections (IFI) are a major cause of morbidity and mortality in patients with cancer. A retrospective analysis of children with cancer at high risk for IFI treated at Mu\u00a8nster University Hospital showed that the incidence (7.4% <jats:italic>vs.<\/jats:italic> 1.8%) and lethality (28.1% <jats:italic>vs.<\/jats:italic> 0) of documented IFI were lower in patients receiving systemic antifungal prophylaxis with liposomal amphotericin B (l\u2010AmB) in comparison to a historical control group. To determine whether this decline in incidence and lethality was due to antifungal prophylaxis or was produced by advances in diagnostic procedures and early empirical antifungal therapy, a prospective study was initiated. Patients in the prophylaxis arm received thrice\u2010weekly 1\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup> body weight 1\u2010AmB, whilst patients in the early intervention arm received no prophylaxis. Diagnostic procedures and antifungal therapy for suspected or proven IFI were initiated as clinically indicated for all patients. The primary endpoint of the study was the incidence of IFI. Secondary endpoints were the use of therapeutic doses of l\u2010AmB, the safety of prophylactic l\u2010AmB, and the total consumption of l\u2010AmB for antifungal therapy. The interim analysis after 1\u2003year showed no differences between the two approaches with respect to the incidence of IFI and to safety issues.<\/jats:p>","DOI":"10.1046\/j.1439-0507.2001.00706.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T14:48:16Z","timestamp":1047480496000},"page":"455-463","source":"Crossref","is-referenced-by-count":29,"title":["Liposomal amphotericin B for prophylaxis of invasive fungal infections in high\u2010risk paediatric patients with chemotherapy\u2010related neutropenia: interim analysis of a prospective study"],"prefix":"10.1111","volume":"44","author":[{"given":"S.","family":"Uhlenbrock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Fegeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"J\u00fcrgens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,21]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(96)92700-0"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01967060"},{"key":"e_1_2_5_4_2","first-page":"143","volume-title":"Systemische Pilzinfektionen: Diagnostik, Prophylaxe und Therapie.","author":"Jaschonek K.","year":"1993"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90441-5"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90594-0"},{"issue":"2","key":"e_1_2_5_7_2","first-page":"70","article-title":"Mykose\u2010Prophylaxe bei neutrozytopenischen Patienten","volume":"37","author":"Arning M.","year":"1994","journal-title":"Mycoses"},{"key":"e_1_2_5_8_2","first-page":"48","volume-title":"Pilzinfektionen in der Onkologie.","author":"Ritter J.","year":"1996"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(88)80343-7"},{"key":"e_1_2_5_10_2","first-page":"778","article-title":"Invasive aspergillosis during chemotherapy in children","volume":"36","author":"B\u00f6melburg T.","year":"1994","journal-title":"Haematol. Blood Transfusion"},{"key":"e_1_2_5_11_2","unstructured":"Uhlenbrock S.(2000)\u00dcber die antimykotische Prophylaxe und Therapie bei p\u00e4diatrischen Hochrisikopatienten mit chemotherapieinduzierter Leukozytopenie \u2013 Interimsanalyse einer prospektiven randomisierten Studie.Inaugural Dissertation WWU M\u00fcnster."},{"key":"e_1_2_5_12_2","first-page":"661","volume-title":"P\u00e4diatrie.","author":"Ritter J.","year":"2001"},{"issue":"2","key":"e_1_2_5_13_2","first-page":"8","article-title":"Aspekte zur Diagnostik tieflokalisierter, opportunistischer Mykosen","volume":"37","author":"Fegeler W.","year":"1994","journal-title":"Mycoses"},{"key":"e_1_2_5_14_2","first-page":"179","article-title":"Special aspects related to invasive fungal infections in children with cancer","volume":"2","author":"Ritter J.","year":"1995","journal-title":"Bailli\u00e8res Clin. Infect Dis"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701543"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.2473063.x"},{"key":"e_1_2_5_17_2","first-page":"577","article-title":"Randomized double\u2010blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients","volume":"12","author":"Tollemar J.","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401004"},{"key":"e_1_2_5_19_2","first-page":"321","article-title":"Fungal infections in paediatric haematology","volume":"40","author":"Hann I.","year":"2001","journal-title":"Haematol. Blood Transfusion"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1439-0507.2001.00706.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1439-0507.2001.00706.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1439-0507.2001.00706.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T11:27:28Z","timestamp":1693481248000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1439-0507.2001.00706.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":18,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["10.1046\/j.1439-0507.2001.00706.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1439-0507.2001.00706.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}